Pallawi Torka: Phase II Trial of Frontline Therapy for Older Adults with Hodgkin Lymphoma
Pallawi Torka, Assistant Attending at Memorial Sloan Kettering Cancer Center, shared a post on X about a recent paper by her and colleagues published in Journal of Clinical Oncology:
“Thrilled to share our Journal of Clinical Oncology article.
Phase II Trial of Nivolumab Plus Doxorubicin, Vinblastine, Dacarbazine as Frontline Therapy in Older Adults With Hodgkin Lymphoma.
Key points:
In older adults ≥60 years treated with nivo-AVD x 6-
- 3y PFS 79%
- 3y OS 97%
- Febrile neutropenia 8% (GCSF recommended)
- No correlation between baseline geriatric impairments and survival outcomes or toxicities (relatively fit cohort)
- PET-2 was not predictive of PFS or OS.
Nivo-AVD is the SOC for OA with cHL
Unanswered
- Tolerability in vulnerable OA
- Very limited data in patients >80 years of age
- Patients with controlled autoimmune conditions?
- Long-term PFS and OS, late side effects
- Disease course after relapse
RWE needed to answer these.
Thank you to Alison Moskowitz, Gilles Salles, Paul Hamlin, MSK Department of Medicine, Memorial Sloan Kettering Cancer Center for their mentorship!”
Authors: Pallawi Torka, Tatyana Feldman, Kerry Savage, Heiko Schöder, Alison Moskowitz et al.
More posts featuring Pallawi Torka.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023